Quantcast

Latest Idenix Pharmaceuticals Inc. Stories

2009-07-20 15:05:00

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2009. At June 30, 2009, Idenix's cash, cash equivalents and marketable securities totaled $51.7 million. Business Highlights Idenix announced today that it had successfully...

2009-07-14 15:05:00

CAMBRIDGE, Mass., July 14 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the second quarter of 2009 on Monday, July 20, 2009 after U.S. financial markets close. In conjunction with the issuance of the press release, Idenix management will host a conference call at 4:30 p.m. ET on Monday, July 20, 2009 to discuss the company's financial results for the second quarter of 2009 and provide an update on the...

2009-05-11 15:05:00

CAMBRIDGE, Mass., May 11 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the upcoming Deutsche Bank 2009 Health Care Conference on Monday, May 18, 2009 at 8:40 a.m. ET at the Intercontinental Hotel, Boston. The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes...

2009-04-30 15:05:00

CAMBRIDGE, Mass., April 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2009. At March 31, 2009, Idenix's cash, cash equivalents and marketable securities totaled $64.5 million. Business Highlights In the first quarter of 2009, the company announced that it had...

2009-04-23 06:00:00

CAMBRIDGE, Mass., April 23 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported data from its three hepatitis C development programs being presented this week at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. These presentations include data on IDX184, a once-daily, oral...

2009-04-03 15:05:00

CAMBRIDGE, Mass., April 3 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that management will present an overview of the company's three hepatitis C programs at the Canaccord Adams Hepatitis C Conference on Tuesday, April 7 at 9:45 a.m. ET at the InterContinental The Barclay New York Hotel in New York City. The live and archived webcasts of the presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com....

2009-03-18 15:06:00

CAMBRIDGE, Mass., March 18 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that four abstracts from the company's hepatitis C antiviral discovery and development programs have been accepted for presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL, April 22-26, 2009 in Copenhagen,...

2009-02-17 15:05:00

CAMBRIDGE, Mass., Feb. 17 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the fourth quarter and year ended December 31, 2008. At December 31, 2008, Idenix's cash, cash equivalents and marketable securities totaled $46.1 million. Business Highlights Idenix successfully completed a...

2009-02-11 15:30:00

CAMBRIDGE, Mass., Feb. 11 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the fourth quarter of 2008 on Tuesday, February 17, 2009 after the U.S. financial markets close. In conjunction with the issuance of the press release, Idenix management will host a conference call at 4:30 p.m. ET on Tuesday, February 17, 2009 to discuss the company's financial results for the fourth quarter of 2008. To access the...

2009-02-06 06:00:00

CAMBRIDGE, Mass. and LONDON, Feb. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) and GlaxoSmithKline (GSK) today announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899. IDX899 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase II clinical development being developed by Idenix for the treatment of HIV/AIDS. New NNRTIs are needed to address the increasing prevalence of viral resistance and side effects...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related